Filing Flows › Veracyte (VCYT) › Q3 2026 › vs Q3 2025
Veracyte (VCYT) Q3 2026 vs Q3 2025 (year over year)
Veracyte's revenue rose $19.9M (+15%) from $132M in Q3 2025 to $152M in Q3 2026. The biggest changes: Testing revenue +$18.7M (+15%); Product revenue +$1.3M (+40%); Biopharmaceutical and other revenue −$106K (-13%). Gross margin 70.6% against 69.2% (+1.4 pts).
Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%, net earnings $31.5M, operating cash flow $40.3M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 70.6% | 69.2% | +1.4 pts |
| Operating margin | 10.9% | 17.4% | -6.5 pts |
| Net margin | 20.8% | 14.5% | +6.2 pts |
| Free cash flow margin | 25.0% | 31.8% | -6.8 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Testing revenue | $146M | $128M | $18.7M | +15% |
| Product revenue | $4.6M | $3.3M | $1.3M | +40% |
| Biopharmaceutical and other revenue | $709K | $815K | −$106K | -13% |
| Revenue | $152M | $132M | $19.9M | +15% |
| Gross profit | $107M | $91.3M | $15.8M | +17% |
| Cost of revenue | $44.6M | $40.6M | $4.1M | +10% |
| Other income, net | $4.6M | −$4.1M | $8.6M | — |
| Operating profit | $16.6M | $22.9M | −$6.4M | -28% |
| Operating expenses | $90.5M | $68.3M | $22.2M | +32% |
| Pre-tax earnings | $21.1M | $18.9M | $2.2M | +12% |
| Research & development | $32.2M | $16.0M | $16.2M | +101% |
| Sales & marketing | $28.7M | $24.5M | $4.2M | +17% |
| General & admin | $29.3M | $27.3M | $2.0M | +7% |
| Other operating costs | $422K | $622K | −$200K | -32% |
| Income tax benefit | $10.4M | $248K | $10.1M | 42× |
| Net earnings | $31.5M | $19.1M | $12.4M | +65% |
| Depreciation & amortization | $6.0M | $5.3M | $713K | +14% |
| Share-based compensation | $14.0M | $10.8M | $3.2M | +30% |
| Working capital & other | $11.2M | −$9.6M | $20.8M | — |
| Operating cash flow | $40.3M | $44.8M | −$4.5M | -10% |
| Free cash flow (OCF − capex) | $37.9M | $42.0M | −$4.0M | -10% |
| Capital expenditures | $2.3M | $2.8M | −$458K | -16% |
Questions
How much did Veracyte's revenue grow year over year in Q3 2026?
Veracyte's revenue rose $19.9M (+15%) from $132M in Q3 2025 to $152M in Q3 2026.
What drove Veracyte's revenue change in Q3 2026?
Testing revenue +$18.7M (+15%); Product revenue +$1.3M (+40%); Biopharmaceutical and other revenue −$106K (-13%).